The Syndrome of Food-Cobalamin Malabsorption: A Personal View in a Perspective of Clinical Practice

Emanuel Andres¹, Khalid Serraj², Mustapha Mecili¹, Georges Kaltenbach² and Thomas Vogel²

¹Service Médecine Interne, Diabète et Maladies métaboliques, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
²Service Médecine Interne et Gériatrie, Hôpital de la Robertissau, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Summary

This article presents recent findings on cobalamin deficiencies due to food-cobalamin malabsorption or non-dissociation of vitamin B12 from its carrier proteins syndrome. These findings might be of interest to medical practitioners. This disorder, for which a definitive consensus on the criteria for diagnosis is not yet available, is the leading cause of cobalamin deficiency in the elderly. In practice, food-cobalamin malabsorption is a diagnosis of exclusion, and requires the deductive elimination of all other causes of cobalamin deficiencies, particularly pernicious anaemia. The causes or associated disorders of food-cobalamin malabsorption are multiple and include gastric pathologies, Helicobacter pylori infections and certain drugs (biguanides and proton pump inhibitors). Depending on the disease aetiology, treatment of food-cobalamin malabsorption involves oral supplementation of doses lower than those required for pernicious anaemia.

Keywords: Vitamin B12; Cobalamin; Cobalamin deficiency; Food-cobalamin malabsorption; Oral cobalamin therapy

Introduction

Until the 1990s, the most common recognised cause of cobalamin deficiency in adults was pernicious anaemia [1]. Thanks to progress made during the last 10-20 years in the understanding of vitamin B12 metabolism, “new” physiopathological concepts have emerged or recognized, including a controversial medical concept entitled food-cobalamin malabsorption (FCM) in Anglo-Saxon literature, also known as “syndrome de non-dissociation de la vitamine B12 de ces protéines porteuses” in French literature [2,3]. This clinical condition is the leading cause of cobalamin deficiency in a number of recently published series, especially in elderly patients [4]. It’s to note that currently, FCM continues to be intensively studied and discussed because of the controversial nature of the disorder [3,5].

As this syndrome has been well described for the first time only quite recently (in a complete exhaustive review [4]), we sought to detail the clinical, physiopathological and therapeutic particularities of the FCM syndrome, with a special focus on the works on our group (CARE B12) and in a perspective of clinical practice.

Definition and physiopathological rationale

Vitamin B12, or cobalamin, is found exclusively in animal source foods, and daily intake requirements range from 2 to 5µg [6]. Ingested cobalamin is bound to food proteins and salivary and gastric glycoproteins, such as haptocorrin, in the stomach [7]. The dissociation of vitamin B12 from its carrier proteins and its release as unbound cobalamin are essential prerequisites for its binding to intrinsic factor (Figure 1) an exhaustive and comprehensive review of the cobalamin metabolism is available in reference [7]. FCM is a medical condition that is characterized by the inability to release cobalamin from its carrier proteins [4].

The FCM syndrome was first described by by Doscherholmen in 1973 [8] and well characterized by Carmel and Dawson in the 1990s [4,9]. In some cobalamin-deficient patients, these authors observed conflicting results when employing a modified Schilling test, which uses radioactive cobalamin bound to altered animal proteins (e.g., egg yolk, chicken, salmon), and the normal Schilling, which uses free cobalamin.
Diagnosis criteria cobalamin deficiency related to FCM syndrome:
- Low serum cobalamin levels (<200 pg/mL)
- Normal “standard” Schilling test (using free cyanocobalamin labelled with cobalt-57) or abnormal “modified” Schilling test (using protein-bound radioactive cobalamin) \( \dagger \)
- No dietary cobalamin deficiency (intake > at least 2.5 to 5µg per day)

Presence of a predisposing or associated disorders:
- Atrophic gastritis, chronic *H. pylori* infection, gastrectomy, gastric by-pass
- Exocrine pancreatic insufficiency (mainly related to alcohol abuse)
- Chronic alcohol abuse
- Intake of antacids (H2-receptor antagonists or proton pump inhibitors) or biguanides (metformin)
- Microbial overgrowth, AIDS
- Sjögren’s syndrome, scleroderma
- “Idiopathic” (related to age?) \( \dagger \)

\( \dagger \): The “modified” Schilling test uses food-bound cobalamin (e.g., egg, chicken and fish proteins,...). today, these test are not available in clinical routine.

Table 1: Characteristics of food-cobalamin malabsorption (FCM) syndrome according to Andrés et al. [1,6].

Epidemiology and associated causes

In the Framingham cohort, the prevalence of cobalamin deficiency was estimated between 12% and 20% [11]. Some authors reported a prevalence of 40% among elderly patients living in institutions [1,12]. According to our own experience, the prevalence of cobalamin deficiency (serum levels of cobalamin <200 pg/mL and total homocysteine >13µmol/L) among hospitalized patients for any reason approaches 5%, with FCM accounting for 50% to 60% of cases (with the criteria of FCM reported in Table 1) [1,6]. Figure 2 shows the distribution of cobalamin aetiologies in 160 patients (median age >69 years) followed in an internal medicine department of a tertiary referral university hospital centre [1].

It should be noted, however, that FCM was not mentioned in a number of recently published series on cobalamin deficiencies [13,14], which may be because the clinical entity was not recognized or not scientifically accepted as a true entity. In fact until 1990’s, FCM is an important cause of B12 deficiency that previously has not been appreciated by the general medical community. The scepticism came mainly from the fact that FCM can be diagnosed reliably without actually measuring absorption status. The scepticism came also from the fact that initially FCM was reported to be responsible for a majority of subtle cobalamin deficiencies (with no clinical significance) [15].

As illustrated in Table 1, several causes or “associated” disorders of cobalamin malabsorption have been reported, the most common being age, atrophic gastritis, gastric disease associated with *H. pylori* infection, and the intake of proton pump inhibitors, H2-receptor antagonists, or metformin [4,10].

Table 2: Distribution of various cobalamin deficiency aetiologies in adults (n=160 patients) [2].
neuropathies, or cognitive dysfunctions are frequent manifestations [3,18,23]. Generally, improvement in neuropsychiatric disorders is less marked if the symptoms have been present for a long time, hence the necessity for early diagnosis and prompt cobalamin supplementation [4,5]. However, the absence of any improvement following supplementation should provoke the clinician to question the relation between the reported symptoms and vitamin cobalamin deficiency. Such symptoms could have been owing to causes other than cobalamin deficiency, particularly in elderly subjects with multiple co-morbidities [18].

Besides the aforementioned manifestations, those related to the aetiology of malabsorption should also be considered.

**Positive and aetiological diagnosis**

In theory, only the association of a normal standard Schilling test and an abnormal modified Schilling test will permit a positive diagnosis of FCM [4]. We have previously proposed not consensually accepted criteria to establish the diagnosis (Table 1) [10]. For several authors, the controversy derives from the unproven claim that FCM can be diagnosed reliably without actually measuring absorption status. For these authors, such an idiosyncratic concept is scientifically acceptable only if the criteria were subjected to rigorous comparison against the 'gold standard' of direct tests of food cobalamin absorption testing ("validated" criteria). To date, this was unfortunately not done (exposing several recent published studies to some scepticism). Nevertheless, our criteria permit selection of a homogenous profile of patients with cobalamin deficiency not related to nutritional deficiency, pernicious anaemia and malabsorption [10,18], patients that may benefice from oral cobalamin therapy.

In practice, due to the current non-availability of the Schilling tests, FCM currently remains a diagnosis of exclusion [2]. Once cobalamin deficiency has been documented, the first step towards aetiological diagnosis is to rule out insufficient nutritional cobalamin intake or intestinal malabsorption by taking a thorough food anamnesis and searching for other clinical or biological signs of malnutrition or malabsorption [2,4]. The next step aims to eliminate pernicious anaemia [24], the main differential diagnosis of FCM, by searching for anti-intrinsic factor antibodies and anti-gastric parietal cell antibodies and performing a gastroscopy with systematic biopsies so as to detect auto-immune atrophic funditis [25]. It's important to note that this "deductive elimination" FCM diagnosis process has not been validated in an evidence based medicine approach but may be of interest in routine.

Finally, an explanation of the non-dissociation should be sought and the exact causes and/or associated disorders investigated. Non-dissociation syndrome requires exploration of certain aetiologies or associated disorders, which may be or must be treated in addition to vitamin substitution (in some cases, with a complete and definitive cure of the cobalamin deficiency [see below]. In our experience, FCM is mainly due to iatrogenic causes such as proton pump blockers, H2-blockers, and biguanides, as well as alcohol abuse, gastric diseases, chronic pancreatic insufficiency, and chronic infections such as H. pylori [26,27]. Table 1 shows the complete list of FCM causes or associated disorders that must be search [1,8]. It's to note that in most cases, FCM remains idiopathic.

**Treatment**

When FCM was identified as a major cause of cobalamin deficiency, the usefulness of oral supplementation in managing cobalamin deficiencies, which had previously been treated only by the parental route, was questioned and confirmed [28,29]. It should be noted from a practical point of view that only 1% of crystallin vitamin B12 (free) orally administered is absorbed by a passive diffusion mechanism (independently of intrinsic factor and cubilin) [7,28].

Since 1995, numerous clinical trials confirmed the non-inferiority of the oral route as compared to the parental route in the treatment of FCM, as evidenced by a normalisation of haematological abnormalities and regression of clinical symptoms, particularly neuropsychiatric manifestations, in the majority of patients [28,29]. It's important to keep in mind that early intervention is important to prevent permanent neurological damage. We have recently published an exhaustive review of the efficacy of oral cobalamin therapy in reference [29]. Table 3 summarizes the results of various not blinded, placebo-controlled trials that we conducted with oral cyanocobalamin in the context of FCM management [30-32]. All of the patients who were treated orally corrected their vitamin B12 levels and at least 80% corrected their haematological abnormalities. Moreover, half of the patients experienced a clinical improvement on oral treatment [29-32,34]. It is to note that the effect of oral cobalamin treatment in patients presenting with severe neurological manifestations has not yet been adequately documented [29]. According to our experience and other published series (placebo-controlled trials), oral cyanocobalamin was also effective in pernicious anaemia [33-36]. Sublingual and nasal cyanocobalamin administrations were also tested in vitamin B12 deficient patients, regardless of aetiology, with satisfactory results [37,38].

To ensure rapid correction of cobalamin deficiency and regression of clinical manifestations (particularly neuropsychiatric symptoms), clinical studies revealed that an initial oral daily dose of 1000µg cyanocobalamin during at least 1 week was necessary, followed by 1000 to 2000µg per week during 1 month, then 1000µg once to twice per month [28,29]. However, this dosage regimen has been continuously and markedly decreased in these last years (see or current recommendations in [29], perhaps because absorption by the intrinsic factor-cubilin complex is maintained (for free not-bound cobalamin), and adds to the cobalamin portion that is absorbed by passive diffusion. In one of the studies conducted by the Strasbourg team, patients having received 250 to 500µg/day exhibited favourable biological and clinical responses that were similar in size to those observed with the full dose [31]. A similar observation was later made in several other clinical trials using still lower dose levels [34,36,39]. In 2007, a robust trial demonstrated than an optimal efficacy was obtained with dose levels not exceeding

---

Table 2: Profile of 92 elderly patients with cobalamin deficiency secondary to food-cobalamin malabsorption syndrome [10].

<table>
<thead>
<tr>
<th>Mean age</th>
<th>76±8 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex ratio (women/men)</td>
<td>2</td>
</tr>
<tr>
<td>Main clinical manifestations</td>
<td></td>
</tr>
<tr>
<td>• Sensitive polyneuropathy</td>
<td>45%</td>
</tr>
<tr>
<td>• Cognitive disorders</td>
<td>23%</td>
</tr>
<tr>
<td>• Asthenia</td>
<td>21%</td>
</tr>
<tr>
<td>Main biological manifestations</td>
<td></td>
</tr>
<tr>
<td>• Macrocytosis</td>
<td>53%</td>
</tr>
<tr>
<td>• Anaemia</td>
<td>21%</td>
</tr>
<tr>
<td>• Leucopenia</td>
<td>11%</td>
</tr>
<tr>
<td>• Thrombocytopenia</td>
<td>9%</td>
</tr>
<tr>
<td>• Pancytopenia</td>
<td>6.5%</td>
</tr>
</tbody>
</table>

Table 3: Placebo-controlled trials of oral cyanocobalamin in Pernicious Anaemia.
Therapeutic modalities

- **Oral cyanocobalamin:** 650 µg/day during 3 months
- **Oral cyanocobalamin:** 250 to 1000 µg/day during 1 month
- **Oral cyanocobalamin:** 125 to 1000 µg/day during 1 week
- **Oral cyanocobalamin:** 125 to 1000 µg/day during at least 3 months

Main results

- Normalisation of serum cobalamin levels in 80% of subjects
- Normalisation of serum cobalamin levels in 87% of the subjects
- Normalisation of serum cobalamin levels in all patients treated with >250 µg/day
- Significant 161.6 µg/mL increase of serum cobalamin levels in food-cobalamin group and 136.7 µg/mL in pernicious anaemia

<table>
<thead>
<tr>
<th>Type of study—number of subjects—study population</th>
<th>Therapeutic modalities</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Open prospective study—n = 30</td>
<td>Oral cyanocobalamin: 250 to 1000 µg/day during 1 month</td>
<td>- Normalisation of serum cobalamin levels in 87% of the subjects</td>
</tr>
<tr>
<td>- Retrospective study—n=31</td>
<td>Oral cyanocobalamin: 125 to 1000 µg/day during at least 3 month</td>
<td>- Significant 161.6 µg/mL increase of serum cobalamin levels in food-cobalamin group and 136.7 µg/mL in pernicious anaemia</td>
</tr>
</tbody>
</table>

**Table 3:** Experience on oral food-cobalamin therapy for food-cobalamin malabsorption in the Strasbourg University Hospital, France.

80µg/day but administered for an additional 30 days [39]. Thus for practical issues, we now recommend cyanocobalamin doses of 125 to 1000µg/day for FCM treatment as loading doses and 125 to 500µg/day as maintenance doses [29,34]. However, the recommendation of oral vitamin B12 as a definitive treatment has not yet been fully validated in current clinical practice. To date, several authors suggest that oral vitamin B12 therapy remains one of “medicine’s best kept secrets” [29].

However, it seems logical to differentiate two situations depending on the nature and the reversibility of the diagnosed FCM causes. In a recent work, Kaptan et al. showed that *H. pylori* eradication was sufficient to correct cobalamin deficiency [40]. The duration of cobalamin supplementation would correspond to the period of time required to treat the FCM cause, if the cause could be identified and effectively treated. If no effective treatment is possible, it would be difficult to withhold cobalamin supplementation, notably in the cases of idiopathic malabsorption or the intake of certain drugs that cannot be stopped and/or substituted [1]. In this context, the issue of poor long-term compliance needs to be emphasized: It is necessary to discuss with the patient the benefits and risks of oral administration, taking into account the particularities of each patient and his/her treatment adherence capacity [1,41]. In the event of poor compliance, standard parental treatment is efficacious. Potential allergies (in excipient not in vitamin himself) in the form of cutaneous reactions (rash, urticaria, rare Quincke’s reaction...) to certain oral cobalamin preparations must also be considered. In our experience, oral cobalamin treatment avoids the discomfort, inconvenience and cost of monthly injections.

Vitamin B12 as oral cyanocobalamin is available in tablet forms and as drinkable vials of 250 à 1000µg [29], and is listed in the French Pharmacopoeia and in Vidal with an authorized indication for conditions other than pernicious anaemia (preparations are not covered by Social Security, save IM and drinkable vials).

**Acknowledgements**

To professors Marc Imler and Jean-Louis Schlienger, who initiated the first research program on vitamin B12 in Strasbourg; to the clinicians who allowed the realisation of the clinical studies (CARE B12); and to the French Foundation for its support via the Robert Prize of 2004 and Jacqueline Zittoun, thanks to her knowledge of anaemia and vitamin B12 and folic acid metabolic abnormalities.

**References**